IL6 plays a crucial role in epithelialmesenchymal transition and prometastasis induced by sorafenib in liver cancer.
Oncol Rep
; 45(3): 1105-1117, 2021 03.
Article
en En
| MEDLINE
| ID: mdl-33432366
ABSTRACT
Interleukin6 (IL6) is involved in various biological responses, including tumor progression, metastasis and chemoresistance. However, the role and molecular mechanism of IL6 in the treatment of sorafenib in liver cancer remain unclear. In the present study, through western blot analysis, Transwell assay, flow cytometric assay, ELISA analysis and immunohistochemistry it was revealed that sorafenib promoted metastasis and induced epithelialmesenchymal transition (EMT) in liver cancer cells in vitro and in vivo, and significantly increased IL6 expression. Endogenous or exogenous IL6 affected metastasis and EMT progression in liver cancer cells through Janus kinase 2/signal transducer and activator of transcription 3 (STAT3) signaling. Knocked out IL6 markedly attenuated the prometastasis effect of sorafenib and increased the susceptibility of liver cancer cells to it. In conclusion, the present results indicated that IL6/STAT3 signaling may be a novel therapeutic strategy for liver cancer.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Interleucina-6
/
Transición Epitelial-Mesenquimal
/
Sorafenib
/
Neoplasias Hepáticas
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Oncol Rep
Asunto de la revista:
NEOPLASIAS
Año:
2021
Tipo del documento:
Article